Research ArticleCancer

Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy

See allHide authors and affiliations

Science Translational Medicine  24 Jun 2020:
Vol. 12, Issue 549, eaba2325
DOI: 10.1126/scitranslmed.aba2325

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Immunotherapies combining forces

Although immunotherapy has been achieving increasing prominence in cancer treatment, these methods are not perfect, and many tumors still do not respond to treatment. One approach used for cancer immunotherapy is bispecific antibodies, which recognize a receptor on the surface of T cells and a tumor antigen, helping to bring the two types of cells together and activate the T cells. Building on recent advances in this field, Waite et al. used bispecific antibodies targeting CD28 on T cells and one of two different tumor antigens and then combined them with immune checkpoint therapy, showing that the two treatments reinforce each other.

View Full Text

Stay Connected to Science Translational Medicine